No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 10.5x · 10Y median 8.0x · 83rd percentile · as of Oct 2, 2026
Annualized revenue (TTM) · by quarter, last 10
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-05T10:50:31.056Z. Latest historical point 2026-10-02. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-05T10:50:31.056Z. Latest historical point 2026-10-02. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-05T10:50:31.056Z. Latest historical point 2026-10-02. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-05T10:50:31.056Z. Latest historical point 2026-10-02. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-05T10:50:31.056Z. Latest historical point 2026-10-02.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-05T10:50:31.056Z. Latest historical point 2026-10-02. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-05T10:50:31.056Z. Latest historical point 2026-10-02. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-05T10:50:31.056Z. Latest historical point 2026-10-02. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Hinge Health, Inc. (HNGE) stock was $97.67 as of Oct 2, 2026, 4:00 PM EDT, down 0.28% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +85.0%
Established in 2012 and headquartered in San Francisco, California, Hinge Health, Inc. creates specialized healthcare software solutions for musculoskeletal and joint health.
Medical - Healthcare Information Services · San Francisco, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 3, 2026
29 days away
EPS Estimate
0.60
Revenue Est.
$223.70M
Last Quarter Results
EPS
$0.59
vs Estimate
$0.61
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1HNGE | $7.56B | $97.67 | -0.28% | +84.99% | N/A | N/A | N/A |
| 2OSCR | $8.02B | $30.94 | +3.48% | +60.53% | +11.88% | N/A | vs HNGE |
| 3CHE | $6.63B | $507.50 | +0.91% | +15.43% | +2.45% | +14.08% | vs HNGE |
| 4HIMS | $6.47B | $29.00 | -1.02% | -49.91% | +31.75% | N/A | vs HNGE |
| 5PODD | $9.12B | $131.69 | +0.69% | -57.84% | -14.32% | +12.39% | vs HNGE |
| 6SRRK | $5.61B | $46.81 | +1.41% | +33.05% | +7.90% | N/A | vs HNGE |
21.95
$212.82M
vs Estimate
$201.46M
Consensus Rating
Based on 16 analysts
Average Price Target
$109.31
+11.9% upside
Low
$90.00
Current
$97.67
High
$140.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.54 | $0.60 | $0.73 | 8 |
| Quarter ending Dec 2026 | $0.61 | $0.68 | $0.81 | 8 |
| Quarter ending Mar 2027 | $0.58 | $0.61 | $0.64 | 3 |
| Quarter ending Jun 2027 | $0.69 | $0.72 | $0.75 | 4 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $2.18 | $2.32 | $2.62 | 10 |
| FY 2027 | $2.62 | $2.93 | $3.32 | 9 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $222.48M | $223.70M | $228.25M | 9 |
| Quarter ending Dec 2026 | $226.79M | $238.72M | $248.80M | 9 |
| Quarter ending Mar 2027 | $237.21M | $244.60M | $253.92M | 7 |
| Quarter ending Jun 2027 | $258.11M | $266.16M | $276.29M | 4 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Dec 31, 2026, matching Key Metrics.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $809.51M | $860.36M | $882.87M | 12 |
| FY 2027 | $980.43M | $1.09B | $1.19B | 12 |
